Quality of Anticoagulation With Phenprocoumon and Warfarin in Left Ventricular Assist Device Patients: A Multicenter Study

Author:

Schlöglhofer Thomas123ORCID,Marschütz Angelika12,Combs Pamela4,Stonebraker Corinne4,Lupo Sydney4,Jeevanandam Valluvan4ORCID,Riebandt Julia1ORCID,Schima Heinrich123ORCID,Zimpfer Daniel13ORCID,Meehan Karen4

Affiliation:

1. Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

2. Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria

3. Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria

4. Section of Cardiac Surgery, University of Chicago Medical Center, Chicago, Illinois.

Abstract

Anticoagulation in left ventricular assist device (LVAD) patients is essential to prevent hemocompatibility-related adverse events (HRAEs) but is challenging due to individual variability in dose-response and the small therapeutic window. Primary outcomes were international normalized ratio (INR) time in therapeutic range (TTR) and percentage of tests in range over 1 year after the first follow-up visit (FFUV), and secondary outcomes included all-cause mortality and HRAEs risk factors among phenprocoumon and warfarin users. This retrospective, multicenter study included 179 patients (age: 57.4 ± 11.8 years; female: 23.5%; HeartMate 3/HVAD: 50.8%/49.2%) implanted at the Medical University of Vienna (n = 102 phenprocoumon) and University of Chicago (n = 77 warfarin). Phenprocoumon users had a significantly higher TTR (64.9 ± 16.1% vs. 37.7 ± 21.8%, p < 0.001). One year survival (p = 0.65) and freedom from HRAE (p = 0.54) were comparable for both drugs. A multivariate analysis associated female gender (hazard ratio [HR], 2.15; 95% confidence interval [CI], 1.12–4.11; p = 0.021), no beta blockers at FFUV (HR, 2.16; 95% CI, 1.03–4.52; p = 0.042), gastrointestinal bleeding (GIB) preimplant (HR, 3.41; 95% CI, 1.32–9.45; p = 0.018), and time between INR tests (HR, 0.85; 95% CI, 0.74–0.99; p = 0.03) with a higher risk of HRAEs. To conclude, phenprocoumon versus warfarin users had better anticoagulation quality. Female gender, longer time between INR tests, no beta blockers at FFUV, and GIB preimplant were independent risk factors for HRAEs during LVAD support. Visual Abstract: Summary of key results. INR, international normalized ratio; TTR, time in therapeutic range; PTR, percentage of tests in range; HRAE, hemocompatibility-related adverse event; FFUV, first follow-up visit; GIB, gastrointestinal bleeding; HR, hazard ratio. http://links.lww.com/ASAIO/A961

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Biomedical Engineering,General Medicine,Biomaterials,Bioengineering,Biophysics

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3